Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nolvadex Pediatric Exclusivity Extension Would Block Generics Until 2003

Executive Summary

AstraZeneca expects to receive a pediatric exclusivity extension for the breast cancer agentNolvadex (tamoxifen) based on studies in McCune-Albright syndrome

You may also be interested in...



Barr Tamoxifen Supply Will Hold To Mid-Nov.; Firm Seeks FDA Injunction

Barr will be unable to supply tamoxifen 10 mg after mid-November in the absence of court action to overrule FDA and allow the immediate launch of the firm's generic

Barr Tamoxifen Supply Will Hold To Mid-Nov.; Firm Seeks FDA Injunction

Barr will be unable to supply tamoxifen 10 mg after mid-November in the absence of court action to overrule FDA and allow the immediate launch of the firm's generic

Arimidex Early Breast Cancer sNDA Approval Based On Nolvadex Comparison

AstraZeneca's Arimidex supplemental approval in early breast cancer is based on preliminary analysis of a 31-month efficacy comparison against AstraZeneca's Nolvadex (tamoxifen)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel